Oak Ridge Investments LLC lowered its stake in shares of Aduro Biotech, Inc. (NASDAQ:ADRO) by 36.5% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 432,050 shares of the biotechnology company’s stock after selling 248,849 shares during the quarter. Oak Ridge Investments LLC owned 0.56% of Aduro Biotech worth $4,601,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. raised its position in shares of Aduro Biotech by 5.4% during the 2nd quarter. Vanguard Group Inc. now owns 2,511,995 shares of the biotechnology company’s stock valued at $28,637,000 after buying an additional 129,079 shares in the last quarter. State Street Corp grew its holdings in shares of Aduro Biotech by 8.3% during the 2nd quarter. State Street Corp now owns 684,699 shares of the biotechnology company’s stock valued at $7,808,000 after purchasing an additional 52,597 shares during the last quarter. Baillie Gifford & Co. grew its holdings in shares of Aduro Biotech by 30.8% during the 3rd quarter. Baillie Gifford & Co. now owns 553,090 shares of the biotechnology company’s stock valued at $5,891,000 after purchasing an additional 130,390 shares during the last quarter. Northern Trust Corp grew its holdings in shares of Aduro Biotech by 15.1% during the 2nd quarter. Northern Trust Corp now owns 453,115 shares of the biotechnology company’s stock valued at $5,166,000 after purchasing an additional 59,490 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its holdings in shares of Aduro Biotech by 283.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 372,348 shares of the biotechnology company’s stock valued at $4,244,000 after purchasing an additional 275,295 shares during the last quarter. Hedge funds and other institutional investors own 33.63% of the company’s stock.

In related news, EVP Dirk G. Brockstedt sold 5,877 shares of Aduro Biotech stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $8.00, for a total transaction of $47,016.00. Following the completion of the transaction, the executive vice president now directly owns 75,533 shares of the company’s stock, valued at approximately $604,264. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Jennifer Lew sold 6,600 shares of Aduro Biotech stock in a transaction dated Friday, September 1st. The stock was sold at an average price of $11.70, for a total transaction of $77,220.00. Following the completion of the transaction, the insider now directly owns 49,195 shares of the company’s stock, valued at $575,581.50. The disclosure for this sale can be found here. Over the last three months, insiders have sold 224,480 shares of company stock valued at $2,194,001. 6.60% of the stock is currently owned by corporate insiders.

COPYRIGHT VIOLATION WARNING: “Oak Ridge Investments LLC Lowers Stake in Aduro Biotech, Inc. (ADRO)” was posted by Watch List News and is owned by of Watch List News. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright & trademark legislation. The correct version of this report can be read at https://www.watchlistnews.com/oak-ridge-investments-llc-lowers-stake-in-aduro-biotech-inc-adro/1712005.html.

ADRO has been the topic of several recent research reports. HC Wainwright set a $18.00 target price on shares of Aduro Biotech and gave the company a “buy” rating in a report on Thursday, August 3rd. Zacks Investment Research lowered shares of Aduro Biotech from a “buy” rating to a “hold” rating in a report on Wednesday, August 2nd. BidaskClub lowered shares of Aduro Biotech from a “buy” rating to a “hold” rating in a report on Wednesday, August 2nd. Canaccord Genuity set a $30.00 price target on shares of Aduro Biotech and gave the stock a “buy” rating in a report on Thursday, August 3rd. Finally, William Blair reissued an “outperform” rating on shares of Aduro Biotech in a report on Monday, October 2nd. One analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the company. The company has an average rating of “Buy” and an average price target of $19.14.

Shares of Aduro Biotech, Inc. (NASDAQ:ADRO) traded down $0.20 on Friday, hitting $8.80. 373,989 shares of the stock were exchanged, compared to its average volume of 406,264. Aduro Biotech, Inc. has a 52-week low of $6.01 and a 52-week high of $14.85.

Aduro Biotech (NASDAQ:ADRO) last announced its earnings results on Tuesday, October 31st. The biotechnology company reported ($0.33) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.03). Aduro Biotech had a negative net margin of 548.92% and a negative return on equity of 39.28%. The company had revenue of $3.79 million for the quarter, compared to the consensus estimate of $4.04 million. During the same period in the previous year, the firm posted ($0.54) EPS. The company’s revenue for the quarter was up .0% on a year-over-year basis. sell-side analysts forecast that Aduro Biotech, Inc. will post -1.28 earnings per share for the current fiscal year.

About Aduro Biotech

Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.

Want to see what other hedge funds are holding ADRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aduro Biotech, Inc. (NASDAQ:ADRO).

Institutional Ownership by Quarter for Aduro Biotech (NASDAQ:ADRO)

Receive News & Ratings for Aduro Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro Biotech Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.